Pricing Reports

NICE INSIGHT REPORT

Messenger Ribonucleic Acid, mRNA: 2024 Market Insight, CDMO Pricing and Competitor Benchmarking

Published May 2024
  • Survey of clinical trials currently being conducted, segmented by type and treatment
  • SME analysis and forecasts of biotech fundraising
  • 68 CDMO profiles, including mRNA, chemically synthesized RNA, and LNP manufacturers
  • Pricing for 39 distinct line items
  • mRNA vaccines and therapeutic manufacturing challenges and innovations
  • Detailed information on North American, European, and Asian trials, and exclusive  insights into mRNA, chemically synthesized RNA, and LNP-derived treatments
Learn More
Messenger Ribonucleic Acid, mRNA

The first mRNA clinical trials market survey and pricing study of its kind – 161 pages of primary market research to support your sales team and inform your business strategy, underpinned by exclusive insights into current clinical trials alongside SME and investor forecasts around forthcoming biotech fundraising efforts.

Key market insights for innovators, CDMOs and investors in the mRNA industry.

Essential pricing and market intelligence for CDMOs

Compare prices to your competitors with our strategic pricing study, which breaks down the manufacturing process and industry costs. As investments pour in from both the private and government sectors, learn from leaders in mRNA-based drugs so you can better position your business.

 

Grasp the mRNA Vaccine & Therapeutics pipeline

Our Market Analysis provides an in-depth R&D pipeline report segmented by indication and development stage. Make informed business decisions with our guide to approved mRNA drugs and the developmental and clinical landscape. See where your competitors are from pre-clinical through Phase III trials.